Aer Therapeutics, a clinical-stage biopharmaceutical company based in San Francisco, California, has raised $36 million in a Series A round. The funding was led by Hatteras Venture Partners, with participation from OrbiMed and Canaan.

Aer Therapeutics is developing a novel inhaled approach to treat lung diseases characterized by excess mucus and mucus plugs, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. The company's lead therapeutic candidate, AER-01, has shown promising preliminary safety and efficacy profiles in clinical trials, thanks to the efforts of a research consortium led by Dr. John Fahy's airway biology lab at the University of California San Francisco (UCSF) in collaboration with Dr. Stefan Oscarson's glycochemistry lab at University College Dublin and Dr. Anne Marie Healy's pharmaceutics lab at Trinity College Dublin.

The $36 million Series A funding will enable Aer Therapeutics to further develop and advance AER-01 and its inhaled approach to treating lung diseases, which has the potential to transform the lives of millions of people worldwide who suffer from these debilitating conditions.

With the backing of Hatteras Venture Partners, OrbiMed, and Canaan, Aer Therapeutics is well-positioned to bring its innovative treatments to market and make a significant impact in the field of respiratory medicine. Visit us for more information about their latest funding round: https://founderlodge.com/round/Aer-Therapeutics-Inc-raises-36000000-Series-A-2023-04-17-John-Fahy-MTIyMTg